Zhitong Finance App News, Xianjian Technology (01302.HK) announced that on October 29, 2026, the IBS™ absorbable drug-eluting coronary stent system (IBS™ coronary stent or this product) independently developed by Yuanxin Technology (Shenzhen) Co., Ltd. (Yuanxin), a subsidiary of the Group, has obtained EU CE MDR certification, and is the first iron-based coronary stent system in the world to obtain a sales license.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.